© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
All News
MYC Status Relevant to Risk Stratification in Newly Diagnosed Multiple Myeloma
October 29, 2020
In evaluating MYC rearrangement and its correlation with disease burden and prognostics in newly diagnosed multiple myeloma, a group of Mayo Clinic investigators found that the alteration is associated with high disease burden and independently prognosticates adverse outcomes in patients.
High-Risk MCL Population Represents Unmet Need in Treatment Landscape
October 28, 2020
The treatment landscape of mantle cell lymphoma has been enriched with the development of several targeted therapies, but patients considered to have high-risk disease tend to have a worse prognosis, despite the latest development in the field.
FoundationOne Liquid CDx Granted New and Expanded FDA Indications in Various Solid Tumors
October 28, 2020
The FDA has granted approval to the FoundationOne Liquid CDx as a companion diagnostic indicated for the to identify patients who may derive benefit from treatment with 3 FDA-approved targeted therapies, including alpelisib, rucaparib, and alectinib.
FDA Grants Priority Review to sBLA for Trastuzumab Deruxtecan for HER2+ Metastatic Gastric/GEJ Adenocarcinoma
October 28, 2020
The FDA granted a Priority Review designation to the supplemental Biologics License Application for trastuzumab deruxtecan as treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
Tweet Chat Recap: Selecting Treatment for a HER2-Positive Metastatic Breast Cancer Case Scenario
October 28, 2020
During a recent tweet chat, Sara M. Tolaney, MD, MPH, joined Targeted Oncology for the discussion of a 39-year-old woman with relapsed/refractory HR-negative/HER2-positive metastatic breast cancer.
Adjuvant Osimertinib Induces Promising CNS DFS in Early Stage EGFR-Mutant NSCLC
October 27, 2020
In an interview with Targeted Oncology, Masahiro Tsuboi, MD, discussed the findings for the ADAURA study, which explored the role of osimertinib as treatment of patients with early-stage EGFR-mutant non-small cell lung cancer following a complete tumor resection.
Novel IDH1 Inhibitor Demonstrates Safety and Preliminary Efficacy in R/R AML
October 26, 2020
The IDH1 inhibitor olutasidenib showed a favorable safety profile in patients with relapsed/refractory acute myeloid leukemia treated in a phase 1/2 clinical trial, according to topline results.
Adagrasib Demonstrates Significant Disease Control in KRAS G12C+ Non-Small Cell Lung Cancer
October 26, 2020
Adagrasib demonstrated promising antitumor activity as monotherapy in patients with previously treated KRAS G12C–mutant non–small cell lung cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.
New and Updated Data in GI Cancer Trials Show Continued Benefit With Targeted and Immunotherapy Agents
October 26, 2020
Historically, in gastrointestinal malignancies, chemotherapy and radiation were utilized to improve outcomes for patients. Although these treatments were effective, disease recurrence was always imminent, demonstrating a need for novel therapies.
FDA Approves Companion Diagnostic for Identification of NTRK Fusions in Solid Tumors
October 26, 2020
The FDA granted approval to the FoundationOne®CDx as a companion diagnostic for the identification of NTRK fusions across all solid tumors for the approved larotrectinib.